Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2024 02:00 ET | Source: NACON

PRESS RELEASE: BIGBEN WEEK 2024: NACON PRESENTS AN AMBITOUS LINE-UP AND ANNOUNCES A NEW DEPARTMENT DEDICATED TO RACING

BIGBEN WEEK 2024 NACON PRESENTS AN AMBITOUS LINE-UP AND ANNOUNCES A NEW DEPARTMENT DEDICATED TO RACING During the annual Bigben Group event, NACON has announced the creation of a department...
May 30, 2024 02:00 ET | Source: NACON

COMMUNIQUE DE PRESSE: BIGBEN WEEK 2024: NACON PRÉSENTE UN LINE UP AMBITIEUX ET ANNONCE UN NOUVEAU PÔLE DÉDIÉ AU RACING

- BIGBEN WEEK 2024 – NACON PRÉSENTE UN LINE UP AMBITIEUX ET ANNONCE UN NOUVEAU PÔLE DÉDIÉ AU RACING Lors de l’événement annuel du Groupe Bigben, NACON annonce la création d’un département dédié...
May 28, 2024 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate...
May 28, 2024 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...
May 23, 2024 08:30 ET | Source: Inozyme Pharma Inc.

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
May 22, 2024 08:00 ET | Source: Esperion Therapeutics, Inc.

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

– NILEMDO (bempedoic acid), a First-In-Class, Oral Treatment and NUSTENDI (bempedoic Acid / Ezetimibe Fixed-Dose Combination) Receive Label Update Approval from The European Commission as Treatments...
May 20, 2024 06:00 ET | Source: Esperion Therapeutics, Inc.

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in...
May 15, 2024 14:15 ET | Source: Osten & Victor Alberta Tennis Centre

Osten & Victor Alberta Tennis Centre launches Everyone Can Play Program to create inclusivity promoting tennis as a sport for everyone

CALGARY, Alberta, May 15, 2024 (GLOBE NEWSWIRE) -- Today, The Osten & Victor Alberta Tennis Centre (The ATC) held a press conference to announce the launch of its new Everyone Can Play program,...
May 15, 2024 07:00 ET | Source: Sportradar AG

Sportradar Reports First Quarter 2024 Financial and Operating Results

Achieved Record Revenue of €266 Million, Up 28% and Grew Adjusted EBITDA 29% Raising 2024 Outlook for Revenue and Adjusted EBITDA Commencing Purchases Under Previously Announced Share Repurchase...
May 14, 2024 08:00 ET | Source: Tenax Therapeutics

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF ...